Geron Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GERN research report →
Range $4 – $8
Price Chart
About the company
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies.
- CEO
- Harout Semerjian
- IPO
- 1996
- Employees
- 258
- HQ
- Foster City, CA, US
Get TickerSpark's AI analysis on GERN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $560.94M
- P/E
- -12.42
- Fwd P/E
- 10.24
- PEG
- -0.27
- P/S
- 2.58
- P/B
- 2.58
- EV/EBITDA
- -26.57
- Div Yield
- 0.00%
- Gross Margin
- 91.59%
- Op Margin
- -8.18%
- Net Margin
- -23.04%
- ROE
- -22.27%
- ROIC
- -3.92%
Latest fiscal year · YoY change
- Revenue
- $183.88M+138.8%
- Gross Profit
- $179.14M+136.5%
- Op Income
- $-53,835,000
- Net Income
- $-85,782,000+50.9%
- EPS
- $-0.13+51.9%
- OCF Growth
- +49.2%
- FCF Growth
- +49.3%
- 52W High
- $2.01
- 52W Low
- $0.84
- 50D MA
- $1.14
- 200D MA
- $1.40
- Beta
- 0.61
- RSI (14)
- 35
- Avg Volume
- 12.91M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Geron reported another quarter of RYTELO growth, beat on disciplined spending, and reiterated confidence in hitting the high end of 2026 revenue guidance despite ending the IMpactMF study.· November 4, 2026
- Q3 net product revenue was $60.1 million, up 27% year over year, with 10% quarter-over-quarter demand growth.
- RYTELO expanded to more than 1,700 prescribing accounts, driven mainly by community practices, and management said it now has four straight quarters of demand growth.
- Gross-to-net improved to 19.3% from 21.6% a year ago, while total operating expenses fell to $48.3 million from $60.1 million.
- Geron raised full-year 2026 operating expense guidance to $220 million-$230 million from $230 million-$240 million and reiterated revenue guidance of $220 million-$240 million, expecting the mid- to high end.
- The company discontinued the Phase III IMpactMF trial after an independent committee said it was unlikely to meet its overall-survival endpoint; management said there were no new safety signals.
Third-quarter 2026 total net product revenue was $60.1 million, compared with $47.2 million in Q3 2025, representing 27% year-over-year growth. Gross-to-net deductions were 19.3% versus 21.6% a year ago. R&D expense was $12.7 million, down from $21.1 million; SG&A was $35.7 million, down from $39 million; and total operating expenses excluding COGS were $48.3 million versus $60.1 million. Cash, cash equivalents, restricted cash and marketable securities were $339 million at September 30, 2026, up from $327 million at June 30, 2026. Management reiterated 2026 RYTELO net revenue guidance of $220 million to $240 million, saying it expects to land in the mid- to high end, and lowered total operating expense guidance to $220 million to $230 million. Gross-to-net for the remainder of 2026 is expected to be in the low to mid-20s.
Harout Semerjian framed the quarter as evidence that Geron is executing on a longer-term RYTELO strategy: steady U.S. demand growth, expansion into Europe, and continued financial discipline. He emphasized that the company wants consistent quarter-over-quarter growth rather than a single inflection point, and said there are still thousands of patients who could benefit from RYTELO. On business development, he said the company’s cash and operating base now give it flexibility to pursue hematology/oncology assets selectively.
Michelle Robertson highlighted a strong balance sheet and said the company is in a position to make targeted, disciplined investments. She cited $339 million of cash, cash equivalents, restricted cash and marketable securities at quarter-end, compared with $327 million at the end of Q2. She also noted the quarter’s gross-to-net improvement to 19.3%, lower R&D and SG&A expenses year over year, and said 2026 guidance was tightened to $220 million-$230 million in total operating expenses while revenue guidance stayed at $220 million-$240 million.
Analysts pressed on whether RYTELO growth could accelerate beyond the recent consistent quarter-over-quarter pattern; management replied that the strategy is to sustain steady growth and that they are satisfied with the current trajectory. Questions also focused on what the lower OpEx means for future investment and whether savings from ending IMpactMF would be redeployed; management said next year spending should rise somewhat as Europe scales and post-marketing commitments continue. Another theme was business development: management said it is looking for community-focused hematology/oncology assets and described the opportunity as a 'string of pearls' approach rather than large-scale acquisitions. Analysts also asked about Europe versus the U.S.; management said Germany is attractive because of reimbursement dynamics, orphan status, and differences in treatment patterns, and said RYTELO’s ex-U.S. opportunity remains meaningful.
The call reinforced that RYTELO is gaining traction, with four straight quarters of demand growth, more than 1,700 accounts, and management confidence that the franchise can keep growing for years. The company also has $339 million in cash, better gross-to-net, and lower operating expenses, giving it room to fund Europe launch efforts and selective business development.
The IMpactMF trial was stopped because the independent committee believed it was unlikely to meet its overall-survival endpoint, which removes a potential upside program. Growth remains steady rather than accelerating, and management acknowledged that Europe will require staged investment and that next year OpEx may rise as commercialization and post-marketing work expand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.6%
- Shares Outstanding
- 644.24M
- Float Shares
- 558.08M
of shares held by institutions
268 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 50.57M | ▲ 1.45M |
| Ra Capital Management, L.P. | 42.81M | ▼ 20.96M |
| Soleus Capital Management, L.P. | 42.81M | ▲ 1.30M |
| Vanguard Group Inc | 35.66M | ▲ 1.24M |
| State Street Corp | 31.90M | ▼ 3.96M |
| Citadel Advisors LLC | 29.04M | ▲ 7.46M |
| Vanguard Capital Management LLC | 27.67M | ▲ 422.01K |
| Clearbridge Investments, LLC | 19.70M | ▲ 49.67K |
| Eversept Partners, LP | 18.72M | ▼ 117.46K |
| Goldman Sachs Group Inc | 16.63M | ▲ 5.46M |
| Geode Capital Management, LLC | 14.27M | ▼ 285.59K |
| Nantahala Capital Management, LLC | 13.87M | ▲ 1.65M |
Held by 240 ETFs
Biggest fund positions in GERN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Williams Timothy | buy | 12,000 |
| Nov 13, 26 | Semerjian Harout | buy | 53,500 |
| Sep 30, 26 | Spiegel Robert J. | other | 6,351 |
| Jun 30, 26 | Spiegel Robert J. | other | 6,103 |
| May 20, 26 | Spiegel Robert J. | other | 220,000 |
| May 20, 26 | O'Farrell Elizabeth G. | other | 220,000 |
| May 20, 26 | Molineaux Susan | other | 220,000 |
| May 20, 26 | McDonald John F | other | 220,000 |
| May 20, 26 | Bir Dawn Carter | other | 220,000 |
| Apr 13, 26 | Williams Timothy | other | 2,500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GERN coverage
Recent articles, reports, and earnings notes.
No research on GERN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GERN report →Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 18
Geron Targets Germany Launch and Deals as RYTELO Sales Grow
marketbeat.com · Nov 10
Geron (NASDAQ:GERN) & MDxHealth (NASDAQ:MDXH) Critical Review
defenseworld.net · Nov 6
Geron: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 5
Geron Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Geron Corporation (GERN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Geron (GERN) Reports Break-Even Earnings for Q3
zacks.com · Nov 4
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
globenewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.